The Library
Browse by Funders
Up a level |
Jump to: E
Number of items: 1.
E
(2015) SWITCH : A randomised, sequential, open-label study to evaluate the efficacy and safety of Sorafenib-sunitinib versus Sunitinib-sorafenib in the treatment of metastatic renal cell cancer. European Urology, 68 (5). pp. 837-848. doi:10.1016/j.eururo.2015.04.017 ISSN 0302-2838.